Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cisatracurium→

Cisatracurium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
96946-41-7
Molecular formula
C53H72N2O12+2
Molecular weight
929.1 g/mol
Drug class
Non-depolarising neuromuscular blockercompetitive nicotinic acetylcholine-receptor antagonist
Mechanism of action
Competitively blocks acetylcholine at nicotinic receptors on the motor end-plate, preventing depolarisation and producing skeletal-muscle relaxation. It does not provide sedation or analgesia.
Indications / reported uses
  • Adjunct to general anaesthesia to facilitate endotracheal intubation and provide skeletal-muscle relaxation during surgery or controlled ventilation
  • Maintenance of neuromuscular blockade in adults and paediatric patients in intensive-care settings when clinically indicated; requires respiratory support and neuromuscular monitoring

Sources: US DailyMed — Cisatracurium besylate injection · NLM MeSH — Cisatracurium · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cisatracurium Environmental Risk Assessment (ERA) (the Cisatracurium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.